Identification and Characterization of \u3cem\u3eOGG1\u3c/em\u3e Mutations in Patients with Alzheimer\u27s Disease by Mao, Guogen et al.
University of Kentucky
UKnowledge
Toxicology and Cancer Biology Faculty
Publications Toxicology and Cancer Biology
2007
Identification and Characterization ofOGG1
Mutations in Patients with Alzheimer's Disease
Guogen Mao
University of Kentucky, gmao2@uky.edu
Xiaoyu Pan
University of Kentucky
Beibei Zhu
University of Kentucky, bzhu2@uky.edu
Yanbin Zhang
University of Kentucky
Fenghua Yuan
University of Kentucky
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/toxicology_facpub
Part of the Medical Toxicology Commons
This Article is brought to you for free and open access by the Toxicology and Cancer Biology at UKnowledge. It has been accepted for inclusion in
Toxicology and Cancer Biology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Mao, Guogen; Pan, Xiaoyu; Zhu, Beibei; Zhang, Yanbin; Yuan, Fenghua; Huang, Jian; Lovell, Mark A.; Lee, Maxwell P.; Markesbery,
William R.; Li, Guo-Min; and Gu, Liya, "Identification and Characterization of OGG1 Mutations in Patients with Alzheimer's Disease"
(2007). Toxicology and Cancer Biology Faculty Publications. 32.
https://uknowledge.uky.edu/toxicology_facpub/32
Authors
Guogen Mao, Xiaoyu Pan, Beibei Zhu, Yanbin Zhang, Fenghua Yuan, Jian Huang, Mark A. Lovell, Maxwell P.
Lee, William R. Markesbery, Guo-Min Li, and Liya Gu
Identification and Characterization of OGG1 Mutations in Patients with Alzheimer's Disease
Notes/Citation Information
Published in Nucleic Acids Research, v. 35, no. 8, p. 2759-2766.
© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Digital Object Identifier (DOI)
http://dx.doi.org/10.1093/nar/gkm189
This article is available at UKnowledge: https://uknowledge.uky.edu/toxicology_facpub/32
Published online 10 April 2007 Nucleic Acids Research, 2007, Vol. 35, No. 8 2759–2766
doi:10.1093/nar/gkm189
Identification and characterization of OGG1
mutations in patients with Alzheimer’s disease
Guogen Mao1, Xiaoyu Pan1, Bei-Bei Zhu2, Yanbin Zhang1, Fenghua Yuan1,
Jian Huang5, Mark A. Lovell3,4, Maxwell P. Lee6, William R. Markesbery2,3,
Guo-Min Li1,2 and Liya Gu1,2,*
1Graduate Center for Toxicology, 2Department of Pathology & Laboratory Medicine, 3Sanders-Brown Center
on Aging, 4Department of Chemistry, University of Kentucky, Lexington, KY, USA, 5College of Life Sciences,
Wuhan University, Wuhan, China and 6Laboratory of Population Genetics, National Cancer Institute, Bethesda,
MD, USA
Received January 31, 2007; Revised and Accepted March 15, 2007
ABSTRACT
Patients with Alzheimer’s disease (AD) exhibit
higher levels of 8-oxo-guanine (8-oxoG) DNA
lesions in their brain, suggesting a reduced or
defective 8-oxoG repair. To test this hypothesis,
this study investigated 14 AD patients and 10 age-
matched controls for mutations of the major 8-oxoG
removal gene OGG1. Whereas no alterations were
detected in any control samples, four AD patients
exhibited mutations in OGG1, two carried a common
single base (C796) deletion that alters the carboxyl
terminal sequence of OGG1, and the other two had
nucleotide alterations leading to single amino acid
substitutions. In vitro biochemical assays revealed
that the protein encoded by the C796-deleted OGG1
completely lost its 8-oxoG glycosylase activity, and
that the two single residue-substituted OGG1 pro-
teins showed a significant reduction in the glyco-
sylase activity. These results were consistent with
the fact that nuclear extracts derived from a limited
number of AD patients with OGG1 mutations
exhibited greatly reduced 8-oxoG glycosylase
activity compared with age-matched controls and
AD patients without OGG1 alterations. Our findings
suggest that defects in OGG1 may be important in
the pathogenesis of AD in a significant fraction of
AD patients and provide new insight into the
molecular basis for the disease.
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of
adult dementia and is characterized by progressive
cognitive deterioration, impairment of activities of daily
living, and a variety of neuropsychiatric symptoms and
behavioral disturbances. It is generally accepted that the
production and accumulation of beta-amyloid peptide in
the brain in AD are important in the pathogenesis of the
disease (1). Increasing evidence supports that mutations in
the beta-amyloid precursor protein and the presenilins
lead to some early-onset AD cases (1). Although
mutations can be induced by numerous endogenous and
exogenous agents, oxidative stress has been thought to be
the main source for DNA damage in AD (2). Indeed,
previous studies have demonstrated that increased nuclear
and mitochondrial DNA oxidation is present in the brain
in AD (3–6), with 8-hydroxyguanine or its isomeric form
7,8-dihydro-8-oxoguanine (8-oxoG) being the major
DNA lesion (7).
The 8-oxoG is highly mutagenic because adenine is
preferentially incorporated opposite the oxidized base
upon replication by DNA polymerases, yielding GC
to TA transversions. To prevent 8-oxoG-induced muta-
genesis, cells possess a mechanism called the GO system,
which consists of MutY homolog (MYH), OGG1
(8-oxoG-DNA glycosylase I, the eukaryotic homolog of
MutM), and MutT (8–10). The MutT protein is a
phosphotase that specifically converts 8-oxo-dGTP in
the nucleotide pool into 8-oxo-dGMP to keep the
oxidized nucleotides from being incorporated into
DNA during replication. Both MYH and OGG1 are
8-oxoG-specific DNA glycosylases. Unlike MutT, OGG1
and MYH are components of base excision repair and
involved in processing 8-oxoG (9,10). Whereas, OGG1
actually removes 8-oxoG from damaged DNA, MYH
excises the adenine residues incorporated by DNA
polymerases opposite 8-oxoG. Mutations of OGG1 and
MYH have been implicated in the development of certain
human diseases including cancer (11–13). Gene knockout
mice defective in OGG1 accumulate higher levels of
8-oxoG lesions compared with wild-type controls
*To whom correspondence should be addressed. Tel: þ1 859 323 0285; Fax: þ1 859 323 1059; Email: lgu0@uky.edu
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
(14,15), and exhibit elevated spontaneous mutations,
especially when exposed to higher levels of oxidative
stress (16). These observations suggest that OGG1 acts as
a major pathway responsible for 8-oxoG removal (17).
To determine the impact of OGG1 in AD development,
DNA and/or protein samples derived from the brain of
AD patients and age-matched controls were analyzed for
defects in OGG1 and OGG1 glycosylase activity.
Mutations of the OGG1 gene were indeed identified
in AD patients. Biochemical studies revealed that these
mutations either completely inactivate or severely reduce
the OGG1 DNA-glycosylase activity, suggesting that
defects in OGG1 are associated with the development
of AD.
MATERIALS AND METHODS
AD sample collection
Brain specimens were from AD patients and normal
control subjects who were longitudinally followed with
annual detailed assessments in the University of Kentucky
Alzheimer’s Disease Center. The specimens were evalu-
ated in a blinded manner in our study. These samples were
collected as described previously (3). Briefly, 10–15 g
specimens of frontal, temporal and parietal lobes and
cerebellum were dissected en bloc at the time of autopsy
from patients with AD and age-matched normal control
subjects. The tissue was snap-frozen and stored at 708C
until used for analysis. All AD patients met standard
clinical diagnostic criteria for probable AD (18) and
accepted histopathological criteria for the diagnosis of
AD (19). The AD patients were in the late stage of AD.
Control subjects were individuals without a history of
dementia, other neurological disorders or systemic
disease affecting the brain. Neuropathological studies
revealed no significant neuropathological alterations in
the control subjects. The mean age for the control cases
was 92.3 and 72.0 years for the AD cases. The average
postmortem interval was 2.90 0.31 h for AD and
3.36 0.47 h for control subjects.
OGG1 activity assay
Preparation of nuclear extracts from brain specimens was
performed as described previously (20). Because of
potential variations in water content in tissues collected
from various individuals (both AD and control subjects),
data were normalized to protein content for each isolated
nuclear fraction, rather than using the same amount
of starting materials for extract preparations. The OGG1
glycosylase activity was measured essentially as described
(21) using an oligonucleotide duplex consisting of the
32P-labeled 50-ATTGCCATTCTCGATA[8-oxoG]GATC
CGGTCAAACCTAGAC-30 and the cold complementary
strand 50 GTCTAGGTTTGACCGGATCCTATCGAG
AATGGCAAT-30. Briefly, incision reactions (20ml) con-
tained 50mM sodium phosphate buffer (pH 6.8), 2mM
EDTA, 2mM DTT, 80mM KCl, 0.1mg/ml of BSA, 10%
glycerol, 50 fmol of 32P-labeled duplex and 40 mg of
nuclear extracts or indicated amount of purified wild-type
or mutant OGG1 protein. After incubation at 378C for
1 h, the reactions were terminated by adding an equal
volume of a stop solution (95% formamide, 20mM
EDTA, 0.05% bromophenol blue and 0.05% xylem
cyanol). The reaction products were resolved on a 15%
denaturing gel and visualized by a phosphorimager.
Site-directed mutagenesis, overexpression and purification
of OGG1
The His-tagged human OGG1 expression vector (pET28d)
was kindly provided by Drs Sankar Mitra and Tapas K.
Hazra, University of Texas Medical Branch at Galveston.
Construction of the OGG1 mutants associated with AD
was performed using an overlap-extension PCR technol-
ogy as described (22), which is depicted in Figure 1,
showing the strategy for the generation of the
C796-deletion of OGG1. Two sets of PCR primers
were used: forward primer 1 (RP1), 50-GGGGAATTGT
GAGCGGATAAC-30, and reverse primer 1 (RP1),
50-ATATGGACATCCACGGCACAGCCTGGGGC
TT-30; FP2, 50-AGGCTGTGCCGTGGATGTCCATAT
GT-30 and RP2, 50-GGTGGTGGTGGTGCTCGAG-30,
where the bold types represent the mutation site. PCR
products from the two sets of reactions were mixed,
denatured and reannealed. Because these PCR products
overlapped at their 30 ends, a full-length mutant OGG1
was generated via 30 end extension (Figure 1). The full-
length mutant gene was amplified using primers FP1 and
RP2, digested with XhoI and XbaI, and cloned into the
XhoI/XbaI-digested pET28d expression vector. The C796
deletion results in a frame-shift mutation that allows the
mutated gene to encode a protein 59 amino acids longer
than the wild-type OGG1 (see below for details). Thus, a
pair of primers (50-ACTGTCACTAGTCTCACCAG-30
and 50-ATACTCGAGTCAATATCCCCCACCCCATCT
TGTTG-30) were used to amplify part of the exon 7
sequence of OGG1 and its 30 untranslated region (30-UTR)
from genomic DNA derived from patient AD2.
After digestion with BspMI and XhoI, the PCR product
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Figure 1. Diagram of PCR-based site-directed mutagenesis. Deletion of
a C from C796 C797 C798 in OGG1 is shown as an example.
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was cloned into pET28d plasmid containing the C796-
deleted OGG1. The presence of the C796 deletion and the
extended 30UTR was confirmed by DNA sequencing.
Other OGG1 mutants identified in AD were similarly
constructed.
The wild-type and mutant OGG1 plasmids were
transformed into Escherichia coli strain BL21 DE3 for
expression and the recombinant proteins were purified
as described by Hill et al. (23). The purified proteins
(498% purity, as judged by Coomassie Brilliant Blue
R-250 staining on an SDS-PAGE gel) were aliquoted and
stored at 808C for use.
Single-strand conformational polymorphism and DNA
sequencing analyses
Nuclear DNA was isolated from brain regions of AD
patients and controls as described by Gabbita et al. (3).
PCR-based single-strand conformation polymorphism
(SSCP) was used to determine mutations in OGG1. PCR
primers (Supplementary Data, Table S1) were used to
amplify all seven exons and flanking splice sites of the
OGG1 gene as described by Murata et al. (24). Variant and
wild-type PCR products were excised and eluted
from SSCP gels, and then reamplified. The resulting
PCR products were sequenced using T7 Sequenase,
version 2.0 DNA sequencing kit (USB Corp., Cleveland,
OH, USA).
Statistical analysis
Statistical analyses were performed using t-test function in
R package. Specifically, one-sided t-test was used to
compare 8-oxoG glycosylase activity shown in Figure 2
and 8-oxoG lesion level in Table 1.
RESULTS
Reduced 8-oxoGDNA glycosylase activity in AD patients
The abundance of 8-oxoG in the brain of AD patients
prompted us to determine 8-oxoG glycosylase activity in
AD patients. Nuclear extracts obtained from the brain
specimens of AD patients were examined for their ability
to cleave a duplex DNA containing a single 8-oxoG lesion.
As shown in Figure 2, the nuclear extracts derived from all
three age-matched controls (C1, C2 and C3) exhibited
high levels (8% or more) of 8-oxoG glycosylase activity,
whereas extracts from two (AD2 and AD3) of the three
AD patients tested had only about one-half of the
glycosylase activity observed in the control samples.
These results were repeatable. Statistical analysis revealed
that the observed difference in glycosylase activity between
extracts derived from AD patients with lower 8-oxoG
glycosylase activity (AD2 and AD3) and those isolated
from control subjects (C1-3) or an AD patient with
normal glycosylase activity (i.e. AD1) is highly significant
(P¼ 0.00298). These observations suggest that reduced
repair of 8-oxoG is associated with AD patients.
OGG1mutations in AD patients
Because the major DNA glycosylase for removal of
8-oxoG is OGG1 (17), we reasoned that the reduced
8-oxoG glycosylase activity in AD patients could be due
to a reduction in OGG1 activity. PCR primers
(Supplementary Data, Table 1) were therefore designed
to amplify all seven individual exons of the OGG1 gene
from the brain specimens of AD patients and age-matched
controls. The resulting PCR products were analyzed by
SSCP as described (24). Whereas, no abnormal SSCP
products were detected in exons 1-4, 6 and 7 of OGG1 in
all samples tested (data not shown), two AD patients
appeared to display aberrant SSCP bands in exon 5. As
shown in Figure 3A, two specific products (bands 1 and 4),
presumably the normal alleles of the OGG1 exon 5, were
seen in the age-matched controls (data for C1 and C2 not
shown) and patient AD1 but both normal and additional
alleles (bands 2 and 3) were detected in AD2 and AD3, the
two AD patients exhibiting reduced 8-oxoG glycosylase
activity (Figure 2). These results seem to suggest a
heterozygous alteration of OGG1 in these patients.
To determine if the abnormal SSCP products of exon
5 in AD2 and AD3 were associated with mutation(s),
SSCP bands 1–4 shown in Figure 3A were eluted from
the gel, reamplified and sequenced. As expected, bands 1
and 4 from all samples indeed showed the wild-type OGG1
sequence, and examples of these sequences are shown in
Figure 3B (see two gels on the left side for AD1 and C3).
However, bands 2 and 3 exhibited a mutated OGG1
sequence as a C (C796, C797 or C798) was deleted from
nucleotide positions 796–798. For simplicity, the mutation
was referred to as C796-deleted. Interestingly, both AD2
and AD3 carried the same deletion (Figure 3B, two gels on
the right side). The status of the heterozygous mutation in
AD2 and AD3 was further confirmed by cloning the PCR
products of exon 5 into a T-A cloning vector (Invitrogen,
Carlsbad, CA, USA), followed by DNA sequencing.
0 8.7 4.0 4.2 8.08.0 11
AD
1
AD
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Figure 2. The 8-oxoG glycosylase activity of nuclear extracts derived
from brain of AD patients. Nuclear extracts (40 mg) from AD patients
(AD1, AD2 and AD3) or age-matched controls (C1, C2 and C3) were
incubated with 50 fmol of 32P-labeled 36-mer duplex containing a
centrally located 8-oxoG residue. 8-oxoG cleavage activity in AD
patients, except AD1, was lower than that in age-matched controls.
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The results revealed an approximate 1:1 ratio of wild-type
and mutant clones (data not shown).
The association of a defective OGG1 in AD2 and AD3
prompted us to investigate 11 additional AD samples for
mutations in OGG1. Abnormal SSCP products were
identified in two patients (data not shown). DNA
sequencing analysis revealed that one patient (AD4) had
a G157!A transition and another patient (AD5) carried a
C863!T transition in OGG1 (Figure 3C). The G!A
substitution changes amino acid residue alanine53 (A53) to
threonine and the C!T substitution changes alanine288
(A288) to valine. However, no nucleotide alterations were
identified in any of the seven additional age-matched
controls (C4 in Figure 3C, data for C5–C10 not shown).
Taken together, our results suggest that a substantial
fraction (28.6% or 4 out of 14) of AD patients are
associated with mutations in the OGG1 gene.
The C796-deletedOGG1 gene encodes a proteins lacking
8-oxoG glycosylase activity
Given a single nucleotide deletion in the OGG1 gene, AD2
and AD3 were expected to express an altered OGG1
protein that possesses a carboxyl terminal different from
that of the wild-type OGG1. The wild-type OGG1 gene
encodes 345 amino acid residues (Figure 4A). However,
the C796 deletion altered the coding frame of OGG1 at the
mutation site. As a result, the translation does not
terminate at codon 346, instead, it terminates 59 amino
acid residues downstream of the previous termination site
(Figure 4B). Thus, not only does the mutated protein
contain different amino acid residues from the wild-type
OGG1 following the mutation site, but also is 59-residue
bigger than OGG1 (Figure 4B). The mutant protein was
therefore referred to as OGG1-59aa.
To determine if the mutated OGG1 retains 8-oxoG
glycosylase activity, site-directed mutagenesis was per-
formed to generate the OGG1-59aa as described in
Materials and Methods section. Both the wild type and
AD
1
AD
2
AD
3
C3
1
2
3
4
Nonspecific
product
AD1 (band 1) C3 (band 1) AD2 (band 2) AD3 (band 2)
C798C797C796
G A T C G A T C G A T C G A T C
G A T C G A T C G A T C G A T C
C4
(WT)
AD4
(G157→A)
A
B
C
C4
(WT)
AD5
(C863→T)
Figure 3. Mutations of OGG1 identified in AD patients. (A) SSCP
analysis of AD patients and age-matched controls. Whereas, samples
with higher levels of 8-oxoG cleavage activity (AD1 and C3) exhibited
two specific SSCP products (bands 1 and 4), samples with lower levels
of 8-oxoG cleavage activity showed two additional products (bands 2
and 3). (B) C796 deletion in AD2 and AD3. The indicated SSCP bands
from patients or controls were eluted, PCR-amplified and sequenced.
(C) Base–base substitutions in AD4 and AD5. Arrows point to the
altered nucleotides.
Figure 4. Locations of the identified mutations in OGG1. (A) Partial
protein and DNA sequences of wild-type OGG1. (B) Partial protein
and DNA sequences of OGG1-59aa. Mutation site and original stop
codon are highlighted. Recognition sequence of the restriction
endonuclease BspMI is also highlighted, which was used to clone
part of the exon 7 and 30-UTR sequences from patient AD2 into
pET28d plasmid. (C) Partial DNA and peptide sequences of mutants
A53T and A288V. Important functional domains (modified from
www.sanger.ac.uk/cgi-bin/Pfam/swisspfamget.pl?name¼O15527) of
OGG1 are also shown.
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OGG1-59aa proteins were purified (Figure 5A) and
assayed for the 8-oxoG glycosylase activity. Whereas,
the wild-type OGG1 (W) was very active in cleaving the
8-oxoG-containing duplex, little such activity was detected
in reactions with OGG1-59aa (M), regardless of the
reaction incubation time and the amount of protein used
(Figure 5B and C). Mixing experiments using various
ratios of wild-type OGG1 versus OGG1-59aa indicated
that the mutant protein had no negative inference on the
wild-type OGG1 activity (data not shown), ruling out a
dominant negative role for OGG1-59aa. These results
indicate that a defective OGG1 is present in patients AD2
and AD3, which may account for the reduced 8-oxoG
glycosylase activity in these patients.
OGG1 with A53T or A288V substitution possesses
a reduced 8-oxoG glycosylase activity
To determine the impact of A53T or A288V substitution
on OGG1 glycosylase activity, genes encoding
OGG1(A53T) and OGG1(A288V) were created using a
similar strategy as described in Figure 1, and the mutant
proteins were purified (see Figure 5A) and examined for
8-oxoG glycosylase activity. Unlike OGG1-59aa, which is
completely defective in 8-oxoG glycosylase activity, both
OGG1(A53T) and OGG1(A288V) proteins were capable
of cleaving the 8-oxoG-containing oligonucleotide duplex
(Figure 6A and B). However, the glycosylase activity of
both altered proteins was only 50–60% of the wild-type
OGG1 activity (Figure 6C). Further analysis revealed that
both mutant proteins possess a Km higher than that of the
wild-type OGG1 (Figure 6D), indicating that the reduc-
tion in glycosylase activity for both mutant proteins is due
to the reduction in enzyme’s affinity to the DNA substrate.
Although protein samples of patients AD4 and AD5 were
not available for biochemical assays, our results strongly
suggest that reduced 8-oxoG glycosylase activity was
likely present in the brain of these AD patients.
DISCUSSION
Patients with AD have been shown to exhibit a much
higher level of 8-oxoG DNA lesions in brain than age-
matched normal control subjects (7). The increased level
of 8-oxoG lesions in AD is likely due to reduced DNA
repair in these patients. We provide here both the genetic
and biochemical evidence that a significant fraction
(28.6%) of AD patients examined in this study exhibited
mutations in the 8-oxoG removing gene OGG1 and that
OGG1 proteins with the mutations identified in AD
patients have either no or greatly reduced 8-oxoG
glycosylase activity.
Interestingly, of four unrelated patients with OGG1
mutations, two (AD2 and AD3) had a C796 deletion
mutation, which changes the OGG1 reading frame and
leads to a different carboxyl terminal sequence, including
an extra fragment of 59 amino acid residues (Figure 4).
This mutation completely abolishes the OGG1 glycosylase
activity (Figure 5). This result is consistent with previous
crystal structure studies of the human OGG1 protein.
Bruner et al. (25) demonstrated that the 8-oxoG lesion is
extruded from the DNA helix and inserted into an
extrahelical pocket composed of amino acid residues
Phe319, Gln315, Gly42 and Cys253 of OGG1. In this active-
site pocket, Phe319 and Cys253 sandwich the 8-oxoG lesion
via interactions with the lesion; the Gln315 amide-NH2
and a water molecule tightly bound to the residue
cooperate to recognize O6 of the oxoG; and the side-chain
carbonyl of Gln315 and a second tightly bound water form
hydrogen bonds with N1, NH2 and O
6 of the oxoG (25).
In addition, residue Asp268 is required to deprotonate
Lys249 and His270 is needed to protonate Lys249, which
acts to displace the oxoG base and to promote conjugate
elimination of the 30 phosphodiester through Schiff base
chemistry (25). However, the C796 deletion alters the
OGG1 reading frame beginning at amino acid residue 267,
leading to a protein no longer containing these important
residues (i.e. Asp268, His270, Gln315 and Phe319) at the
corresponding positions (see Figure 4A and B). Therefore,
A
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Figure 5. OGG1-59aa has no glycosylase activity. 8-OxoG glycosylase
activity was determined as described in the Figure 2 legends, but using
purified proteins. (A) SDS-PAGE of purified recombinant wild-type
and mutant OGG1 proteins, as indicated. (B) 8-oxoG glycosylase
activity of wild-type OGG1 (W) and OGG1-59aa (M) using the
indicated amount of proteins. Reactions were incubated at 378C for
30min. (C) Time course of 8-oxoG glycosylase activity assays of OGG1
(W) and OGG1-59aa (M). Each reaction contained 1.25 fmol of the
indicated proteins.
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it is understandable that the OGG1-59aa has no 8-oxoG
glycosylase activity.
Two additional OGG1 mutations, A53T and A288V,
were also identified in AD patients and both were found
to reduce 8-oxoG glycosylase activity (Figure 6). The
observed activities for these mutants appear to be justified
by the roles of A53 and A288 in the OGG1 structure.
OGG1 has two important domains (see Figure 4C):
the OGG-N domain partially contributes to the
8-oxoG-binding pocket and the HhH-GPD domain
(a helix–hairpin–helix structural element followed by a
Gly/Pro-rich loop and a conserved aspartic acid) provides
both the catalytic and DNA-binding functions of the
DNA glycosylase (26–28). A53 is located in the region
linking two b sheets (b B and b C) in the OGG-N domain,
and A288 is part of the polypeptide connecting two
a-helices (a M and a N) involved in the catalytic activity
of the glycosylase (25). Thus, both alanine residues are not
in the active center of their corresponding domains.
However, substitutions of these alanines with other
residues may allow OGG1 to adapt a conformation that
is slightly different from the wild-type conformation,
leading to the observed reduced glycosylase activity.
Whether or not these alterations represent polymorphism
in the population remains to be defined. It is also
important to determine if individuals with these types of
OGG1 alterations are at higher risk to develop AD.
It is interesting that, although a defective OGG1 was
detected in the brain of patients AD2 and AD3, extracts
derived from these tissues still contained partial 8-oxoG
glycosylase activity (Figure 2). This phenomenon could be
attributed to two possibilities. First, the alteration is a
heterozygous mutation, thus, the patients possessed both
wild-type and mutant OGG1. This possibility is supported
by the fact that both wild-type and mutant alleles of
the OGG1 exon 5 were detected in patients AD2 and AD3
(Figure 3A) and that the mutant OGG1 protein does
not interfere with the wild-type protein on its glycosylase
activity (data not shown). A second explanation is that
there are multiple 8-oxoG glycosylase activities in
human cells. Evidence for this assumption came
from gene knockout mice defective in OGG1. Although
Ogg1/ mice manifest a steady-state level of 8-oxoG that
is 3- to 10-fold higher than wild-type controls (14,15),
there is slow but significant removal of 8-oxoG
from proliferating Ogg1-null cells (29), indicating that
alterative 8-oxoG repair pathways are present in mamma-
lian cells. Indeed, such activities have been recently
identified (17,30).
The presence of multiple 8-oxoG glycosylase activities
in mammalian cells may also explain why some AD
patients who were previously shown to exhibit higher
levels of 8-oxoG lesions in brain (3–6) seemed to be
normal in OGG1 glycosylase activity, implying that
deficiency in other 8-oxoG removal pathway(s) may also
contribute to the high level of 8-oxoG in AD. Previous
studies have shown significant differences in 8-oxoG levels
between AD patients and age-matched controls (3–6).
Interestingly, when 8-oxoG levels reported previously
(3–6) were compared between AD patients with and
without OGG1 mutations, it was found that the 8-oxoG
level in AD with OGG1 alterations was higher than that in
those without OGG1 alterations (Table 1). And t-test
analysis revealed that the difference in 8-oxoG levels
Figure 6. Reduced glycosylase activity in OGG1(A53T) and OGG1(A288V). Unless otherwise mentioned, 8-oxoG glycosylase activity was assayed in
a 20-ml reaction containing 25 fmol of wild-type (W) or mutant (M) OGG1 and 50 fmol of oligonucleotide duplexes containing a single 8-oxoG.
Reactions were incubated at 378C for 1 h. (A) Time course of glycosylase activity of OGG1(A53T). (B) Time course of glycosylase activity of
OGG1(A288)V. (C) Comparison of glycosylase activities among various OGG1 proteins. Each point represents the average value of three
independent experiments, and error bars show SDs. (D) OGG1(A53T) and OGG1(A288V) possess a Km that is higher than that of OGG1.
Reactions were assembled similarly as described in panels A and B, but incubated at 378C for 30min and in the presence of increasing DNA
concentrations as indicated.
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between these two groups is highly significant as judged
by P¼ 0.025. These data indicate that whereas OGG1 is
the major 8-oxoG removal enzyme, abnormality in other
8-oxoG removal pathway(s), and 8-oxoG tolerance
(MYH) and cleansing (MutT homologs) pathways can
also result in accumulation of the oxidized lesion. The
identification of only 28.6% AD patients with OGG1
alterations also support the possibility that the remaining
71.4% of the AD patients could have mutations in MYH,
MutT homologs and/or other 8-oxoG removal pathways.
Although this hypothesis remains to be investigated,
our results shown here indicate that defects in DNA
repair, including the OGG1 pathway, are present in AD
patients, providing a possible molecular basis for the
development of AD.
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